# Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

> **NCT02009332** · PHASE1,PHASE2 · COMPLETED · sponsor: **Aadi Bioscience, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Non-muscle Invasive Bladder Cancer (NMIBC)

## Interventions

- **DRUG:** ABI-009
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02009332
- **Lead sponsor:** Aadi Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-09
- **Primary completion:** 2019-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02009332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02009332, "Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02009332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*